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Abstract
Purpose Metastatic non-small cell lung (NSCLC) cancer represents one of the most common types of brain metastasis. The 
mechanisms involved in how circulating cancer cells transmigrate into brain parenchyma are not fully understood. The aim 
of this work was to investigate the role of fucosylated carbohydrate epitopes CD15 and sialyated CD15s in cancer adhesion 
to brain-derived endothelial cells and determine their influence in blood–brain barrier (BBB) disruption
Methods Three distinct, independent methods were used to measure brain endothelial integrity and include voltohmmeter 
(EVOM™), impedance spectroscopy (CellZscope®) and electric cell-substrate impedance sensing system (ECIS™). Two 
fucosyltransferases (FUT4 and 7) responsible for CD15 and CD15s synthesis were modulated in four human cancer cell 
lines (three lung cancer and one glioma).
Results Overexpression of CD15 or CD15s epitopes led to increase in adhesion of cancer cells to cerebral endothelial cells 
compared with wild-type and cells with silenced CD15 or CD15s (p < 0.01). This overexpression led to the disruption of 
cerebral endothelial cell monolayers (p < 0.01). Knockdown of FUT4 and FUT7 in metastatic cancer cells prevented disrup-
tion of an in vitro BBB model. Surprisingly, although the cells characterised as ‘non-metastatic’, they became ‘metastatic’ 
-like when cells were forced to over-express either FUT4 or FUT7.
Conclusions Results from these studies suggest that overexpression of CD15 and CD15s could potentiate the transmigra-
tion of circulating NSCLC cells into the brain. The clinical significance of these studies includes the possible use of these 
epitopes as biomarkers for metastasis.
Keywords CD15 · CD15s · NSCLC · Brain metastasis · FUT4 · FUT7
Introduction
The majority of intracranial tumours are secondary metas-
tases originating from primary non-central nervous system 
(non-CNS) cancers. 20–40% of patients with systemic can-
cers develop secondary brain tumours [1, 2]. The highest 
incidence of brain metastasis is seen in lung cancer patients 
(40–50%) followed by breast (20–30%) and melanoma 
(5–10%) [1, 3, 4]. As overall survival in patients with pri-
mary non-CNS cancers has improved, the incidence of 
metastasis to the brain has also increased, possibly due to 
circulating cancer cells which persist despite patient remis-
sion. The central nervous system (CNS) is considered a 
site of refuge as cancers are protected from most systemic 
therapies by the blood–brain barrier (BBB). The BBB is a 
Samah A. Jassam and Zaynah Maherally shared the first 
authorship.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1106 0-019-03188 -x) contains 
supplementary material, which is available to authorized users.
 * Helen L. Fillmore 
 helen.fillmore@port.ac.uk
1 Cellular and Molecular Neuro-Oncology Research Group, 
School of Pharmacy and Biomedical Sciences, University 
of Portsmouth, White Swan Road, Portsmouth P01 2DT, UK
2 Neuro-Surgery, King’s College Hospital, Denmark Hill, 
London SE5 9RS, UK
 Journal of Neuro-Oncology
1 3
dynamic and selective defensive barrier, which maintains a 
highly specific environment within the CNS by inhibiting 
both fluctuations of plasma components and entry of sub-
stances that may potentially cause brain toxicity [5]. Brain 
vascular endothelial cells are specific to the BBB with low 
pinocytosis and no fenestrations [6] and these cells may play 
a crucial role in the homing process of brain metastasis from 
breast cancer [7] and melanoma [8]. Although, leukocyte-
like mechanisms have been suggested in the extravasation 
process of some cancer cells [9, 10], the transmigration 
of cancer cells particularly to the brain has not been thor-
oughly investigated. Recently, we have characterised CD15 
and CD15s (sialyl CD15) expression in non-small cell lung 
cancer cells and their potential importance in adhering to 
brain derived endothelial cells using a model that mimics 
physiological blood flow [11, 12]. CD15 and CD15s, also 
known as  Lewisx and sialyl  Lewisx respectively, are classi-
fied as Type II Lewis antigens and are synthesized by spe-
cific fucosyltransferases [13]. To gain a better understanding 
on the role of CD15 and CD15s in lung cancer metastasis to 
the brain, two fucosyltransferases, FUT4 and 7, responsible 
for their corresponding synthesis were genetically modu-
lated in non-small cell lung cancer cells. The effect of these 
genetically modified cells on endothelial cell adhesion and 
on integrity of an in vitro BBB model was then evaluated.
Materials and methods
Cell culture
The human cerebral microvascular endothelial cell line 
(hCMEC/D3) was donated by Professor Couraud (Institute 
of Cochin, INSERM, Paris, France) [14] and cultured in 
endothelial basal medium-2 (EGM-2) (Lonza, Germany) 
supplemented with 2% human serum (Sigma, UK). Primary 
NSCLC cells (COR-L105) were purchased from Sigma, UK; 
metastatic NSCLC cells from cervical lymph node (NCI-
H1299) from ATCC, UK and low-passage biopsy-derived 
brain-metastatic NSCLC cells, obtained from a patient with 
lung-brain metastatic cancer (SEBTA-001) as well as a 
biopsy-derived primary glioblastoma (GBM) cell line (UP-
007) both established “in house”. Cell lines were maintained 
at 5%  CO2 and in a humidified atmosphere at 37 °C. All 
lines were subjected to routine mycoplasma testing, and cell 
authentication [15].
Antibodies
Mouse monoclonal anti-CD15 (MEM-158) (Santa Cruz Bio-
technology, USA) was used at the following dilutions: 1:100 
for immunocytochemistry (ICC) and 1:10 for flow cytometry 
(FC). Mouse monoclonal anti-sialyl CD15 (BD Biosciences, 
UK) was used at the following dilutions: 1:50 for ICC and 
1:25 for FC. Secondary antibodies, fluorochrome-conjugated 
Alexa Fluor-488 and 568 IgM (Thermo Fisher Scientific, 
UK) were used for ICC and FC at 1:500.
Overexpression and knockdown of CD15/FUT4 
and CD15s/FUT7
Overexpression of CD15 and CD15s was carried out by 
transfecting cell lines: SEBTA-001, NCI-H1299, COR-
L105 and UP-007 with human non-viral cDNA contain-
ing a unique construct of alpha (1, 3) fucosyltransferase 
(FUT4): (OriGene, USA, FUT4 (NM_002033) or alpha 
(1, 3) fucosyltransferase (FUT7) (OriGene, USA, FUT7 
(NM_004479). cDNA constructs contained a GFP expres-
sion cassette. Transfection was carried out by using Tur-
boFectin8.0 as per the manufacturer’s protocol (OriGene, 
USA). In parallel, endogenous expression of CD15/FUT4 
and CD15s/FUT7 were knocked down using four different 
human-FUT4 and FUT7 unique 29 mer shRNA constructs 
in pGF-V-RS GFP vectors (OriGene, USA).
Immunocytochemistry
Cells were seeded onto sterile coverslips at 1 × 103/well 
overnight, fixed with 4% paraformaldehyde (PFA) (Sigma, 
UK) followed by three washes with phosphate-buffered 
saline (PBS) (Sigma, UK). Non-specific antigens were 
blocked with 10% goat serum (Sigma, UK) then incubated 
with the primary antibody for 1 h followed by 30 min incu-
bation with their respective secondary antibody (Thermo 
Fisher Scientific UK). Hoechst Blue (Cell Signalling Tech-
nology, UK) was used as nuclear counterstain. Coverslips 
were examined using a Zeiss Axio fluorescence microscope 
and images were captured using a Volocity Image Analysis 
Software (V 5.2, Perkin Elmer).
Confocal microscopy
Images were obtained from a Zeiss LSM 510 Meta Axi-
oskop2 confocal microscope (× 40 and × 100 objectives) 
using lasers with excitation wavelengths of 405 nm (blue), 
488 nm (green) and 568 nm (red) and with diode, argon 
and HeNe1 lasers respectively. Identical settings were used 
to image negative controls in which primary antibody was 
replaced with non-specific Isotype.
Flow cytometry analysis
Cells were collected via gentle scraping, blocked in 2% goat 
serum/PBS (Sigma, UK) and primary antibodies applied 
while non-specific IgM isotype was added to the negative 
control and incubated for 30 min. Cells were then washed 
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and secondary antibodies (ThermoFisher Scientific, UK) 
applied for 15 min followed by more washes before trans-
ferring to fluorescence-activated cell sorting (FACS) tubes 
(BD Biosciences, UK) containing 5μL of Propidium iodide 
(PI) (Cell Signalling Technology, UK). Samples were ana-
lysed using a 4-color-multiparameter FACS Calibur (BD 
Biosciences-UK). Each experiment was repeated three 
independent times in triplicate. Data were represented as 
percentage of positive cell population.
Adhesion assay
An adhesion assay kit, CytoSelect Tumor-Endothelium 
(Cell Biolabs, UK) was used [11, 12]. Briefly, 1 × 106 brain 
endothelial cells/well were seeded onto a sterile surface 
coated with fibronectin (10 mg/mL). Cells were grown to 
form a complete monolayer. Cancer cells, labelled with a 
green fluorescent dye (Cell Biolabs, UK), were seeded on 
surface of the activated (with 25 pg/mL TNF-α) hCMEC/
D3 monolayer and incubated for 90 min. Non-adherent 
cells were washed thoroughly with pre-warmed PBS. Rep-
resentative adherent cells were assessed using a POLARstar 
OPTIMA microplate reader (BMG LABTECH, UK). The 
experiment was repeated 3 independent times in triplicate.
Trans‑endothelial migration studies
Voltohmmeter (EVOM™)
Polycarbonate membrane Transwell inserts (24 well, 8.0 μm 
pore size) (Thermo Fisher, UK, UK) were pre-coated with 
10 μg/mL human fibronectin (Sigma, UK) prior to addi-
tion of medium supplemented with TNF-α (25 pg/mL) and 
1 × 105 cells/well of hCMEC/D3 to apical side of the inserts. 
Readings were recorded using a voltohmmeter (EVOM™) 
(World Precision Instruments, USA). When resistance 
reached a plateau, 2.0 × 104 cells/well were added on top 
of the hCMEC/D3 monolayer. Five readings were recorded 
per day and resistance measurement monitored for a further 
5-day period and Ohm’s law applied.
Impedance spectroscopy (CellZscope®)
hCMEC/D3 cells (1 ×  105/well) were seeded on fibronectin-
coated (10 µg/mL) polycarbonate Transwell inserts (24 well, 
8.0 μm pore size) (Thermo Fisher, UK), placed in the CellZ-
scope® module and incubated in a sterile, humidified, 37 
°C and 5%  CO2 incubator. Resistance values were recorded 
using an automated cell monitoring system, CellZscope® 
(nanoAnalytics, UK) until they reached a plateau wherein 
2.0 × 104 cells/well were added on top of the hCMEC/D3 
monolayer. TER values, expressed in Ω · cm2, were recorded 
in real-time over a 5-day period post-addition of cancer cells. 
All experiments were carried out in triplicate and repeated 
at least three times.
Electric cell‑substrate impedance sensing system (ECIS™)
ECIS arrays (8W10E+ , ibidi, Germany) were stabilised with 
l-cysteine (10 nM; 10 min incubation; Sigma, UK), washed 
in Hank’s balanced salt solution (Fisher, UK) and coated 
with 10 mg/mL fibronectin for 2 h followed by seeding of 
7.5 × 104 cells/chamber of hCMEC/D3 in media supple-
mented with TNF-α (25 pg/mL). Resistance was monitored 
using an ECIS Zθ (Applied Biophysics, USA) system until a 
peak resistance was achieved. 2.0 ×  104 of cancer cells were 
then added onto the endothelial cell monolayer. Resistance 
values were obtained in Ω. The confluency of the endothe-
lial cell monolayer was also evaluated by using an Olympus 
1X71 inverted phase contrast microscope.
Statistical analysis
All experiments were performed three times in triplicate, 
and data expressed as + SE. Statistical analyses were per-
formed using One-way ANOVA followed by Tukey’s mul-
tiple comparison post hoc tests using Graph Pad Prism 6 
software for analysis.
Results
Three NSCLC cell lines and one GBM cell line (SEBTA-
001, NCI-H1299, COR-L105 and UP-007) were transfected 
with either a full-length FUT4-GFP for CD15-overexpres-
sion or FUT4 shRNA constructs for CD15-knockdown. 
CD15 protein expression was examined using ICC, and FC 
analyses (Fig. 1a, c). The highest levels of CD15 protein 
expression were seen on the surface of the NSCLC meta-
static cell lines (NCI-H1299 and SEBTA-001), with lower 
cell surface expression in the non-metastatic cell lines 
(COR-L105 and UP-007), consistent with our previous 
report [11]. Expression of CD15 in cells transfected with 
FUT4 shRNA constructs demonstrated knockdown of CD15 
expression (Fig. 1a, c). shRNA knockdown of FUT4 resulted 
in a significant decrease in CD15 positive cells in SEBTA-
001, NCI-H1299, COR-L105, and UP-007 cells (Fig. 1c; 
p < 0.01). In cell lines transfected with FUT4 cDNA con-
structs, there was an increase in CD15 expression (Fig. 1a, 
c). In SEBTA-001 CD15 expression increased from 54.7 to 
92%, in NCI-H1299 from 76 to 90%, in COR-L105 from 23 
to 89% and in UP-007 from 13.4 to 84% (Fig. 1c; p < 0.01).
Using the same four cell lines and methods mentioned 
above, the effects of either over-expressing FUT7 or silenc-
ing FUT7 on CD15s expression was determined. The 
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Fig. 1  CD15 and CD15s expression in FUT4/FUT7-(cDNA and 
shRNA) transfected cells. Target cells (SEBTA-001, NCI-H1299, 
COR-L105 and UP-007) were transfected, either with plasmids con-
taining FUT4 or FUT7-cDNA to induce CD15 or CD15s overexpres-
sion, or with FUT4 or FUT7-shRNA constructs for CD15 or CD15s 
knockdown. a, c FUT4/CD15. b, d FUT7/CD15s. a, b Representative 
confocal images showing localisation of a CD15 or b CD15s (red) 
cells grown on coverslips. c, d Representative FC analysis of CD15 
or CD15s expression. The histograms show percentages of CD15/
CD15s positive cells in wild type controls (blue) where no treatment 
applied, vehicle controls were transfected with non-coding plasmid 
(black), cells transfected with shRNA for FUT4 or FUT7 (red) and in 
cells transfection with cDNA for FUT4 or FUT7 (green). (**P < 0.01) 
difference compared to the wild type. N = 3. No treatment was 
applied to wild type controls and vehicle controls were transfected 
with non-coding plasmids. Scale bar = 20 μm
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absence of CD15s was noted in cells treated with FUT7-
shRNA (Fig. 1b, d). Expression of CD15s was significantly 
decreased post-transfection with FUT7-shRNA in all the 
cell lines: in SEBTA-001, NCI-H1299, COR-L105, and 
UP-007 (p < 0.01). FC analyses results showed a significant 
increase in CD15s expression on cells when transfected with 
FUT7-cDNA. The number of CD15s positive cells increased 
from 55 to 88% in SEBTA-001, 51–78% in NCI-H1299, 
33–53.8% in COR-L105 and 17–45% in UP-007 (Fig. 1d, 
p < 0.01). These results suggest a strong correlation exists 
between genetic manipulation of FUT4/FUT7 and CD15/
CD15s expression.
Following genetic manipulation of FUT4/CD15 or FUT7/
CD15s, changes in cell adhesion to an endothelial cell mon-
olayer hCMEC/D3 was investigated. SEBTA-001 and NCI-
H1299 showed the highest number of adherent cells com-
pared to COR-L105 and UP-007 (Fig. 2a–h). Adhesion of 
cancer cells was significantly reduced following the knock-
down of FUT4/CD15 and the number of adherent cells were 
less compared to the wild type (P < 0.01) (Fig. 2a–d). A sig-
nificant reduction was observed after knockdown of FUT7/
CD15s in SEBTA-001 (2.5-fold decrease) and a 2.7-fold 
decrease in NCI-H1299, a 2.8-fold decrease in COR-L105 
and a 2.8-fold decrease in UP-007 cells compared to the wild 
type (P < 0.01) (Fig. 2e–h). Following the overexpression 
of FUT4/CD15 in SEBTA-001, NCI-H1299, COR-L105 
and UP-007, a significant increase in adhesion (twofold) 
was seen compared to the adhesion of wild type control of 
the same cell line (Fig. 2a–d, p < 0.01). Similar results were 
observed for FUT7/CD15s (Fig. 2e–h, p < 0.01).
We next measured changes in transendothelial electri-
cal resistance (TEER) using three independent technolo-
gies [16]. The EVOM™ technology, often referred to as 
the ‘chop-stick’ method was used to collect data every 2 h 
for 48 h. When wildtype SEBTA-001 and NCI-H1299 cells 
were added to an intact hCMEC/D3 monolayer, a decrease 
in resistance was observed over time and at the 48 h time 
point, this was significant (Fig. 3a, b, e, f; p < 0.01), whereas 
wildtype COR-L105 and UP-007 cells did not cause a 
change in resistance over time (Fig. 3c, d, g, h). Knock-down 
experiments targeting either FUT4 or FUT7 in SEBTA-001 
and NCI-H1299 cells attenuated the changes in resistance 
seen with respective wildtype cells (Fig. 3a, b, e, f).
Enhanced expression of FUT4 or FUT7 in all cell lines 
resulted in a significant decrease in TEER values at 48 h 
(Fig. 3a–h; p < 0.05). Although there appears to be a trend 
towards a decrease in TEER values in UP-007 cells trans-
fected with FUT4, UP-007 cells transfected with FUT7, did 
result in a significant decrease in TEER values at the 48 h 
time point (p < 0.05; Fig. 3d vs. h).
The CellZscope® methodology offers a real-time acqui-
sition of resistance data. Addition of wildtype SEBTA-001 
and NCI-H1299 to an intact monolayer of hCMEC/D3 cells 
resulted in a significant decrease in Transendothelial Resist-
ance TER values over time compared to the non-metastatic 
cell lines, COR-L105 and UP-007 (Fig. 4a–h; p < 0.05. Bar 
graphs represent 24 h). The silencing of either FUT4 or 
FUT7 resulted in the decrease in the ability of SEBTA-001 
and NCI-H1299 to affect hCMEC/D3 monolayer resistance 
(Fig. 4a–h). The overexpression of either FUT4 or FUT7 in 
cell lines tested (except for UP-007 transfected with FUT4), 
when plated onto a stable hCMEC/D3 monolayer, resulted in 
a significant reduction in TER values over time (Fig. 4a–h; 
p < 0.05).
ECIS™ results were consistent with EVOM™ and CellZ-
scope® findings, and a strong association was noted between 
the expression of FUT4/CD15 and FUT7/CD15s and the 
decrease in the resistance of the brain endothelial monolayer. 
ECIS graphs and microscopic images demonstrate the 
changes in resistance of the endothelial cell monolayer, pre- 
and 24 h-post-addition of cancer cells. Addition of wildtype 
SEBTA-001 and NCI-H1299 cells led to a significant reduc-
tion in resistance from 232 to 168 Ω and from 224 to 190 Ω 
(p < 0.05) respectively (Fig. 5a–d). In support of endothelial 
layer disruption, microscopic images show wide gaps in the 
endothelial monolayer barrier (arrows; Fig. 5). Knockdown 
of CD15 and CD15s in SEBTA-001 and NCI-H1299 did 
not result in significant changes to resistance. In addition, 
images of monolayer show a well-structured endothelial 
monolayer (Fig. 5d). Similar to the other methods used for 
measuring BBB integrity, both CD15 and CD15s overex-
pressing cells led to dramatically reduction in resistance 
(Fig. 5a–d; Supplemental Fig. 1a–d).
Discussion
CD15 and CD15s, well characterized for their involvement 
in the homing process of leukocytes, are correlated with can-
cer progression and metastasis in non-CNS cancers [17–19]. 
In previous studies, we showed that CD15 and CD15s are 
involved in the adhesion of cancer cells to brain endothelium 
via CD62E interaction [11, 12]. Here, we wanted to further 
investigate the role of CD15 and CD15s on the potential 
transmigration of cancer cells across an intact brain endothe-
lial monolayer by modulating CD15 and CD15s expression 
by targeting the FUT4 and FUT7 genes.
CD15 and CD15s biosynthesis is regulated by fucosyl-
transferase enzymes (alpha-1,3 FUTs); FUT3,-4,-5,-6,-7 and 
-9, which are spatial and temporally regulated and which 
expression appears to be cell/tissue specific [20–23]. Over-
expression of FUT4 leads to the increase in CD15 expres-
sion and correlates with metastasis in colorectal cancer [24]. 
Conversely, FUT4 knockdown is reported to reduce the 
expression of CD15 in promyelocytes and monocytes [25]. 
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Fig. 2  Adhesion of cancer cells following genetic manipulation of 
CD15 and CD15s. Adhesion of cancer cells following FUT4/CD15 
and FUT7/CD15s manipulation on metastatic NSCLC SEBTA-001 
(a, e), NCI-H1299 (b, f) and non-metastatic NSCLC: COR-L105 (c, 
g), UP-007 (d, h). Cancer cells were incubated for 90 min on a mon-
olayer of activated brain endothelial cells (hCMEC/D3). Non-adher-
ent cancer cells were washed off followed by lysis of cells and quanti-
fied via a microplate reader at 480–520 nm. (**P < 0.01), N = 3
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FUT4 and FUT7 knockdown was shown to significantly 
reduce the trafficking of leukocytes and lymphocytes [26]. 
FUT overexpression in general has been correlated with poor 
prognosis and metastasis in prostate cancer [27–29] as well 
as lung cancer [30].
Overexpression of FUT4/CD15 led to an increase in 
endothelial cell adhesion in all studied cancer cells and 
FUT4/CD15 knockdown resulted in decreased adhesion. 
These findings are in agreement with that of Yang et al. 
[31] where overexpression of FUT4 correlated with high 
metastatic potential in breast cancer cells and implicated 
in adhesion and invasion. Knockdown of FUT4/CD15 and 
FUT7/CD15s significantly reduced the number of adherent 
metastatic and primary lung cancer cells as well as GBM 
cells to brain endothelium.
The findings related to the GBM cell line are very inter-
esting. GBM rarely metastasises to other organs [32]. Mar-
tin et al. in 1995 [32] suggested that the absence in CD15 
expression in GBM cells may contribute to the failure of 
GBM cells to metastasise due to the inability for glioma 
cells to attach to brain endothelial cells. The expression 
dynamics of CD15/CD15s in GBM could help to explain 
Fig. 3  Effects of FUT4/CD15 and FUT7/CD15s modulation on intact 
brain endothelial monolayer assessed by EVOM™. Resistance of 
hCMEC/D3 monolayer in response to cancer cells following FUT4/
CD15 (a–d) and FUT7/CD15s (e, f) genetic manipulation on SEBTA-
001 (a, e), NCI-H1299 (b, f), COR-L105 (c, g) and UP-007 (d, h). 
TEER values decreased when cell lines (except for UP-007) were 
transfected with FUT4/CD15 were placed on an established endothe-
lial cell layer. Similar data were observed for cells transfected with 
FUT7/CD15s.The black bars represents the resistance of endothelial 
monolayer before adding cancer cells, light-grey bars to TEER values 
2 h post-addition of cancer cells, dark-grey bars to TEER values 24-h 
post-addition of cancer cells and white bars to TEER values 48-h post 
addition of applying cancer cells. a–c; *p < 0.01, **p < 0.05. N = 3
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the rarity of GBM extraneural metastasis. Could CD15/
CD15s expression dynamics be a mechanism in which sec-
ondary lesions appear remote from the initial presentation 
site? GBM cells which have exited and entered the periph-
eral circulation may at least in theory, re-enter the brain to 
set up a second lesion site. This re-entry phenomenon if 
proven true may offer a second possibility underlying the 
observation of multiple GBM lesions currently believed to 
be due to invasion of GBM rogue cells. At this stage, this 
theory needs to be further investigated.
While our data suggests a role of CD15/s in NSCLC 
metastasis to brain, there remain questions into mecha-
nisms for trans-endothelial transmigration of cancer cells. 
A likely scenario involves a bi-directional initiation of sig-
nalling cascades leading to the orchestration of processes 
such as the release of enzymes responsible for the break-
down of basal lamina for example. All of which underpin 
migration and invasion into the brain. This is followed by 
colonisation of the brain by interplay between tumour cells 
and the brain micro-environment.
Fig. 4  Effects of FUT4/CD15 and FUT7/CD15s modulation in cells 
on brain endothelial monolayer measured in real-time. Representa-
tive histograms depicting the changes in TEER values, pre and post 
addition of cancer cells using the automated system (CellZscope®). 
The green line represents endothelial cells (control) with no addi-
tion of cancer cells, red line represents FUT4/CD15 overexpressor 
cells (a–d) or FUT7/CD15s (e–h), blue line represents FUT4/CD15 
shRNA transfected cells (a–d) or FUT7/CD15s shRNA cells (e–h), 
yellow line representing the wild type and black line representing the 
blank. Bar chart represents quantified TER values (*P < 0.05), N = 3. 
WT wild type, KO knockdown, OE overexpression
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Recently Zhao et al. [33], identified a prognostic sig-
nature from a comprehensive bioinformatic analyses of 
500 lung adenocarcinoma samples. One of the 20 genes 
highlighted, FUT4, was found to be one of the most sig-
nificant genes associated with poor survival. It would be 
interesting to determine if the FUT genes are associated 
with brain metastases. Another clinical aspect of our 
studies is the potential to use these epitopes as therapeu-
tic targets to prevent cerebral metastases of NSCLC by 
blocking adhesion to brain endothelial cells. While there 
are several temporal doorways for therapeutic targeting 
of metastatic spread, from intravasation to development 
of secondary lesions in the brain, it is generally agreed 
that once in the brain, the lesion is protected from the 
full benefits of treatment due to the blood brain barrier. 
With the advances in biomarkers and in liquid biopsies of 
circulating cancer cells, the possible use of these epitopes 
as biomarkers for metastasis merits further study.
Conclusions
This study sheds light on two fucosyltransferases (FUT4 
and 7) and the role of CD15 and CD15s expression in 
adhesion to and disruption of cerebral endothelial cell 
monolayers. Our data demonstrate that blocking of CD15 
or CD15s expression weakens lung cancer cell adhesion 
and impedes the disruption of an in vitro model of a BBB 
model. Surprisingly, over-expression of these epitopes by 
inducing FUT4 or FUT7 in cell lines not known to be 
Fig. 5  FUT4 and FUT7 knockdown in metastatic cancer cells pre-
vents disruption of intact brain endothelial monolayer. FUT4 in 
SEBTA-001 (a) and NCI-H1299 (b). FUT7 in SEBTA-001 (c) and 
NCI-H1299 (d). a–d Representative histograms showing resistance 
of endothelial barrier in real time, pre and post addition of cancer 
cells measured by (ECIS™). Green line represents control (no cancer 
cells), Red line represents FUT4/CD15 (a, b) or FUT7/CD15s (c, d) 
overexpressing cancer cells, blue line represents knockdown cell lines 
FUT4/CD15 (a, b) or FUT7/CD15s (c, d), yellow line represents 
wildtype cancer cells and black line represents blank no cells. (a–d) 
Bar charts represent quantified resistance values at 24-h pre-post-
addition of cancer cells (*P < 0.05). Lower panel a–d) Representative 
microscopic images demonstrating the changes of integrity in brain 
endothelial monolayer, at time point of 24 h post-addition of cancer 
cells. Red arrows point to areas of endothelial cell monolayer disrup-
tion. Images were obtained using a phase contrast microscope (× 4). 
All studies N = 3
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‘metastatic’ become ‘metastatic-like’ in regards to disrup-
tion of the BBB. While exciting, future in vivo studies are 
needed to confirm our in vitro observations.
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